Chesterbrook, Pennsylvania, October 24, 2017—New research published in two leading diabetes journals demonstrated accuracy and reliability of the OneTouch Verio Flex® blood glucose monitoring (BGM) system, and when the system was used with the OneTouch Reveal® mobile app, it was associated with significant improvements in glycemic control.
In a study just published in the Journal of Diabetes Science and Technology, leading experts in self-monitoring of blood glucose (BG) tested the OneTouch Verio Flex® blood glucose monitoring system and found that the “new system showed a high level of measurement accuracy.” All three lots tested met and exceeded the minimum requirements of the International Organization for Standardization (ISO) 15197:2013 standard for system accuracy. This study follows the publication of another study in the April issue of this same journal that detailed the OneTouch Verio® platform’s seven years of proven accuracy across more than 70,000 clinical data points.
Another study published in the August issue of JMIR Diabetes randomly assigned 128 adults with sub-optimally controlled type 1 and type 2 diabetes based on A1C into two groups: One group switched from their current blood glucose monitoring meter to the OneTouch Verio Flex® blood glucose monitoring system; the other group switched from their current meter to the OneTouch Verio Flex® blood glucose monitoring system combined with the OneTouch Reveal® mobile app. (The OneTouch Verio Flex® blood glucose monitoring system has built-in Bluetooth®[i] Smart Technology that wirelessly connects and transmits results to the OneTouch Reveal® mobile app.) Those who were in the OneTouch Reveal® mobile app group also received texts from a healthcare provider every two weeks, based on a review of OneTouch Reveal® data.
Results suggested improved glycemic control at 12 and 24 weeks in both the meter-only and meter-plus-mobile-app groups compared to baseline, further finding that:
- 88% of the study subjects said the Color Range Indicator on the OneTouch Verio Flex® blood glucose monitoring system together with the OneTouch Reveal® mobile app “could help me stay on track between visits to my health care provider;”
- Improvements using the app were greatest in the participants with type 2 diabetes and those who received the highest number of healthcare provider text messages.
“Use of the OneTouch Verio Flex® meter alone or in combination with the OneTouch Reveal® app was associated with significant improvements in glycemic control after 12 and 24 weeks,” the study authors noted.
The OneTouch Reveal® mobile app is the central component of Diabetes Care from the OneTouch® brand that connects patients to resources beyond blood glucose meters: The OneTouch Reveal® mobile app seamlessly syncs with the OneTouch Verio Flex® blood glucose monitoring system with built-in Bluetooth®[i] Smart Technology. This connectivity enables users to see their blood glucose readings on the mobile app, on their smart device and on their computer through the OneTouch Reveal® web app, and also makes it easier than ever for patients to share their data with their healthcare teams (see infographic). Both the OneTouch Reveal® mobile and web apps visually utilize the same colors as the OneTouch Verio Flex® meter with ColorSure® technology, which uses color to quickly tell the user if a glucose value is in range (green) or above (red) or below (blue) range.
“Self-monitoring of blood glucose is still the most accurate, effective and accessible way people with diabetes can track their blood sugars,” says Dr. Brian Levy, Chief Medical Officer, LifeScan, Inc. “With the OneTouch Verio Flex® blood glucose monitoring system, we are proud to offer people with diabetes and their care teams a very accurate system that they know they can trust. Building on that accuracy, we now have our interconnected diabetes management OneTouch Reveal® system that changes the way patients see their blood sugar. This enables both patients and physicians to use that information to make meaningful decisions about their diabetes management.”
With more than 420,000 total downloads and nearly 45 million blood glucose readings, the OneTouch Reveal® mobile app is the #1 downloaded diabetes app in the U.S., Canada, France, and the U.K. The new version of the OneTouch Reveal® mobile app is available now as a free download for Apple® devices on the App Store® and Android™ devices on Google Play™ in 11 countries globally, including the U.S., Austria, Belgium, Canada, France, Germany, Italy, Ireland, Portugal, Spain, and the United Kingdom.
The OneTouch Reveal® mobile app and OneTouch Verio Flex® blood glucose monitoring system are offerings from the iconic OneTouch® brand by LifeScan, Inc., part of the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring. The JMIR Diabetes study was conducted by LifeScan, Inc. and the Journal of Diabetes Science and Technology study was funded by LifeScan, Inc.
About Johnson & Johnson Diabetes Care Companies (JJDCC)
With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Diabetes Care Companies are a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, Inc., a world leader in blood glucose monitoring; Calibra Medical, Inc., developer of OneTouch Via™ on-demand insulin delivery; and the Johnson & Johnson Diabetes Institute, LLC, a global initiative to improve care and better outcomes worldwide through education and training programs. In the U.S., LifeScan, Inc. is the leading blood glucose monitoring company and OneTouch® brand products are recommended by more endocrinologists and primary care physicians than any other brand. Globally, more than 20 million people depend on OneTouch® brand products to help them manage their diabetes. For more information, visit: www.OneTouch.com.
 Annette Baumstark, PhD, Nina Jendrike, MD, Stefan Pleus, MSc, Christina Liebing, PhD, Cornelia Haug, MD, and Guido Freckmann, MDAccuracy evaluation of a new system for self-monitoring of blood glucose with three test strip lots based on ISO 15197:2013 (Journal of Diabetes Science and Technology (2017) 1-2
 Setford, et al. Seven-year surveillance of the clinical performance of a blood glucose test strip product. Journal of Diabetes Science and Technology (2017) 1-8
 Grady, et al. Diabetes App-Related Text Messages from Health Care Professionals in Conjunction with a New Wireless Glucose Meter With a Color Range Indicator Improves Glycemic Control in Patients With Type 1 and Type 2 Diabetes: Randomized Controlled Trial. JMIR-Diabetes Vol 2, No 2 (2017): Jul-Dec
 Research2Guidance data, October 2017
 Global Brand Equity Insights Study, February 2015
[i] The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by LifeScan Scotland Ltd. is under license. Other trademarks and trade names are those of their respective owners.